TY - UNPB
T1 - Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies - a systematic review
AU - Counotte, M.J.
AU - de Souza Santos, Mariana Avelino
AU - Stittelaar, K.J.
AU - van der Poel, W.H.M.
AU - Gonzales, J.L.
PY - 2021/4/23
Y1 - 2021/4/23
N2 - The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the rapid and successful development of vaccines to help mitigate the effect of the coronavirus disease 2019 (COVID-19) and circulation of the virus. Preclinical vaccine trials provide a wealth of information about the presence and persistence of virus in different anatomical sites. We systematically reviewed all available preclinical SARS-CoV-2 candidate vaccine studies where non-human primates were challenged after vaccination. We found marked heterogeneity in experimental design between the studies. Most of the tested vaccines, only triggered a low or moderate reduction of viral RNA in the upper respiratory tract; We need to consider that most SARS-CoV-2 vaccines that protect against disease might not fully protect against infectiousness and vaccinated individuals might still contribute to SARS-CoV-2 transmission. Careful assessment of secondary attack rates from vaccinated individuals is warranted. Standardization in design and reporting of preclinical trials is necessary.
AB - The outbreak of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the rapid and successful development of vaccines to help mitigate the effect of the coronavirus disease 2019 (COVID-19) and circulation of the virus. Preclinical vaccine trials provide a wealth of information about the presence and persistence of virus in different anatomical sites. We systematically reviewed all available preclinical SARS-CoV-2 candidate vaccine studies where non-human primates were challenged after vaccination. We found marked heterogeneity in experimental design between the studies. Most of the tested vaccines, only triggered a low or moderate reduction of viral RNA in the upper respiratory tract; We need to consider that most SARS-CoV-2 vaccines that protect against disease might not fully protect against infectiousness and vaccinated individuals might still contribute to SARS-CoV-2 transmission. Careful assessment of secondary attack rates from vaccinated individuals is warranted. Standardization in design and reporting of preclinical trials is necessary.
UR - https://osf.io/qt3vx/
U2 - 10.31219/osf.io/u3fwj
DO - 10.31219/osf.io/u3fwj
M3 - Working paper
BT - Assessment of the efficacy of SARS-CoV-2 vaccines in non-human primate studies - a systematic review
PB - OSF Preprints
ER -
